DOCSLIB.ORG

Standard Heparin, Low Molecular Weight Heparin, Low Molecular Weight Heparinoid, and Recombinant Hirudin Differ in Their Ability

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Standard Heparin, Low Molecular Weight Heparin, Low Molecular Weight Heparinoid, and Recombinant Hirudin Differ in Their Ability Gene Therapy (2001) 8, 966–968 2001 Nature Publishing Group All rights reserved 0969-7128/01 $15.00 www.nature.com/gt BRIEF COMMUNICATION Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors UT Hacker1,2,*, FM Gerner1,3,*, H Bu¨ ning1, M Hutter1, H Reichenspurner3, M Stangl4 and M Hallek1,2,5 1Gene Center of the Ludwig-Maximilians-University Munich; 2Medical Department III, 3Department of Cardiac Surgery, 4Department of Surgery, University Hospital Munich/Grosshadern, Ludwig-Maximilians-University, Munich; and 5GSF, National Research Center for Environment and Health, Munich, Germany Recombinant adeno-associated virus type 2 (rAAV) is a and 37.1 ± 1.8% at 1.0 U/ml. The inhibitory effect was sig- promising vector for in vivo gene therapy. Transduction by nificantly weaker compared with heparin at 1.0 U/ml, rAAV requires binding to heparan sulfate proteoglycan on (P Ͻ 0.01). The LMW heparinoid danaparoid inhibited rAAV the cell surface, and heparin can block this binding. Because transduction by 8.8 ± 3.5% at 0.1 U/ml (P Ͻ 0.01 compared heparin is administered to most patients undergoing cardio- with heparin). In contrast, recombinant hirudin did not inter- vascular gene transfer in order to prevent thrombotic events, fere at all with rAAV transduction. In summary, the results it is important to identify anticoagulants which do not inter- demonstrate that inhibition of rAAV transduction by heparin fere with rAAV transduction. Therefore, we examined the occurs rapidly and at therapeutically used concentrations. influence of different anticoagulants on rAAV transduction in LMW heparinoids and above all recombinant hirudin might vitro. rAAV transduction was inhibited by 40.5 ± 7.9% at hep- be alternatives for heparin when vascular gene transfer with arin concentrations of 0.1 U/ml, and by 81.7 ± 3.6% at rAAV requires transient anticoagulation. Gene Therapy 1.0 U/ml. The low molecular weight (LMW) heparin tinzapa- (2001) 8, 966–968. rin inhibited rAAV transduction by 20.2 ± 3.8% at 0.1 U/ml Keywords: adeno-associated virus type 2; anticoagulants; heparin; gene transfer; inhibition Recombinant adeno-associated virus type 2 (rAAV) is a the influence of four anticoagulants, heparin, tinzaparin, viral vector system which allows long-term transgene danaparoid and recombinant hirudin, on the transduc- expression after in vivo application in various tissues.1–5 tion efficiency of rAAV in vitro. Heparin exerts its rAAV has the potential to be used for the treatment of antithrombotic effect through anti-thrombin III (AT III) genetic diseases,4,6,7 cancer gene therapy8,9 and cardio- mediated inhibition of coagulation factor Xa.18 Tinzaparin vascular diseases.10–12 Results demonstrating that rAAV sodium is a low molecular weight (LMW) heparin, pro- can mediate efficient gene transfer into rat arteries10 and duced by enzymatic depolymerization of unfractionated into mouse hearts12 in vivo underline that rAAV might heparin.19 It is a heterogeneous mixture of sulfated poly- be a promising vector for cardiovascular gene therapy. saccharide glycosaminoglycan chains with a mass rang- Recently, heparan sulfate proteoglycan has been pro- ing between 5500 and 7500 daltons. Danaparoid is a posed to be an important attachment molecule13 or recep- LMW heparinoid consisting of heparan sulfate, dermatan tor14 for rAAV. Transduction efficiency of rAAV is sulfate and chondroitin sulfate. Binding to AT III leads decreased in a dose-dependent manner in the presence to an accelerated inhibition of factor Xa resulting in the of heparin by abolishing rAAV binding to, and transduc- antithrombotic effect of danaparoid.20 Hirudin is a potent tion of, target cells.14 Because heparin is administered to thrombin inhibitor originally derived from the medicinal most patients undergoing cardiovascular gene transfer in leech which can now be produced using recombinant order to prevent the incidence of thrombotic events,15–17 technology. Unlike heparin, hirudin acts directly on it is important to identify anticoagulants which do not thrombin, rather than through other clotting factors.21 interfere with rAAV transduction. Therefore, we tested It has recently been demonstrated that heparin can inhibit rAAV-mediated gene transfer in a dose-depen- dent manner by binding to rAAV and thus blocking viral Correspondence: M Hallek, Medical Department III, University Hospital attachment to target cells.14 During vascular interventions Munich/Grosshadern, LMU, Marchioninistr. 15, 81377 Munich, Germany and cardiovascular surgery heparin is routinely used to 15,18 *UTH and FMG contributed equally to this work prevent the incidence of thrombotic events. In order Received 16 January 2001; accepted 19 March 2001 to identify the effects of different clinically used antico- Inhibition of transduction by rAAV vectors UT Hacker et al 967 agulants on rAAV-mediated HeLa cell transduction, we inhibition after a 10 min incubation time. Prolongation of examined the inhibitory effects of heparin, LMW heparin, the incubation time from 10 min to 2 h did not signifi- LMW heparinoid and recombinant hirudin at equipotent cantly enhance the inhibition of transduction (Figure 1a). concentrations. When using heparin at concentrations When using a 10-fold concentrated virus a significantly from 0.1 to 1000 anti-factor-Xa U/ml, rAAV-mediated lower inhibition of transduction of 18.1 ± 1.2% was target cell transduction was blocked up to 100% in a detected at low heparin concentrations of 0.1 U/ml, com- dose-dependent manner (Figure 1a). At concentrations of pared with a one-fold concentrated virus preparation 0.1 U/ml, heparin inhibited viral transduction by (P = 0.029). However, at higher heparin concentrations 40.5 ± 7.9%, and 1.0 U/ml heparin caused 81.7 ± 3.6% (1.0–1000 U/ml) no significant differences could by ident- ified (Figure 2). Taken together, these data confirm the results of Summerford and Samulski,14 and demonstrated that heparin decreased rAAV-mediated target cell trans- duction. Furthermore, they indicate that the inhibition of rAAV transduction efficiency by heparin may be a rel- evant problem in the clinical setting when rAAV is used as a vector system for cardiovascular gene transfer because (1) it occurs at therapeutical heparin concen- trations of 0.1–1 U/ml, (2) the binding of heparin to rAAV is a rapid event, and (3) increasing the viral titer by a factor of 10 can reduce the inhibitory effect of heparin only at a low concentration of 0.1 U/ml. In the presence of the LMW heparin tinzaparin, inhi- bition of target cell transduction was 20.2 ± 3.8% at 0.1 anti-factor-Xa U/ml and 37.1 ± 1.8% at 1.0 U/ml. Nearly complete inhibition occurred only at a high concentration of 1000 U/ml, a dose which is not used clinically. A pro- longation of the incubation time (2 h versus 10 min) had Figure 1 For the generation of rAAV virions, 293 cells (a gift from M no influence on the results (Figure 1b). Compared with Lose, Max-Planck-Institute of Biochemistry, Martinsried, Germany) were heparin, the inhibitory properties of tinzaparin were sig- cotransfected by calcium phosphate precipitation with the plasmids pRC, nificantly weaker at a concentration of 1.0 U/ml containing the AAV rep and cap genes, pGFP, containing the EGFP (P Ͻ 0.01). cDNA (Clontech, Palo Alto, CA, USA) within the adeno-associated virus Danaparoid consists of a mixture of the glycosamino- ITR-sequences (both kindly provided by Anne Girod, Gene Center, Mun- ich, Germany), and pXX6, containing the adenovirus helper genes (kindly glycans heparan sulfate, dermatan sulfate and chondro- provided by RJ Samulski22 University of North Carolina at Chapel Hill, itin sulfate. It is a low molecular weight heparinoid. NC, USA). After 48 h, the cells were lysed and fractioned ammonium Therapeutic concentrations of 0.1 U/ml inhibited HeLa sulfate precipitation was performed. rAAV virions were further purified cell transduction by 8.8 ± 3.5%, (P Ͻ 0.01) compared with and concentrated by ultracentrifugation on a CsCl gradient = heparin (Figure 1c). Full inhibition was obtained at a con- (P 1.37 g/ml) and column chromatography. Genomic titers were determ- centration of 1000 U/ml which is not utilized in in vivo ined by dot blot as described.23 For determination of the infectious titers, HeLa cells were plated in 12-well plates at 7 × 104 cells per well. Twenty- conditions. The incubation time did not significantly alter four hours later the cells were irradiated with 100 Gy and serial dilutions the inhibitory effect of danaparoid (Figure 1c). The differ- of the recombinant virus were added to the cells. After 48 h, the number ences in the inhibitory properties between the com- of GFP-expressing cells was quantified by flow cytometry. Using these pounds can be explained by differences in their chemical × 11 methods, titers up to 8 10 genomic particles/ml and infectious titers composition. Danaparoid is a mixture of heparan sulfate, × 8 of up to 8 10 infectious particles/ml were detected. For the inhibition dermatan sulfate and chondroitin sulfate.20 It has been experiments HeLa cells were pretreated as described above. rAAV at a concentration of 3.2 × 104 infectious particles/ml was incubated with serial demonstrated previously that dermatan sulfate and chon- dilutions of anticoagulants for 10 min or 2 h at room temperature in droitin sulfate exert only weak inhibitory effects on serum-free DMEM (Biochrom, Berlin, Germany). 250 ␮l of these sol- rAAV-mediated target cell transduction.14 utions were then added to the HeLa cells, corresponding to an MOI of 0.1. After a 2 h incubation time, the cells were washed twice with PBS, and DMEM/10% FCS was added.
Load more

Recommended publications
  • Enoxaparin Sodium Solution for Injection, Manufacturer's Standard
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLOVENOX® Enoxaparin sodium solution for injection 30 mg in 0.3 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 40 mg in 0.4 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 60 mg in 0.6 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 80 mg in 0.8 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 100 mg in 1 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 300 mg in 3 mL solution (100 mg/mL), multidose vials for subcutaneous or intravenous injection PrLOVENOX® HP Enoxaparin sodium (High Potency) solution for injection 120 mg in 0.8 mL solution (150 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 150 mg in 1 mL solution (150 mg/mL), pre-filled syringes for subcutaneous or intravenous injection Manufacturer’s standard Anticoagulant/Antithrombotic Agent ATC Code: B01AB05 Product Monograph – LOVENOX (enoxaparin) Page 1 of 113 sanofi-aventis Canada Inc. Date of Initial Approval: 2905 Place Louis-R.-Renaud February 9, 1993 Laval, Quebec H7V 0A3 Date of Revision September 7, 2021 Submission Control Number: 252514 s-a version 15.0 dated September 7, 2021 Product Monograph – LOVENOX (enoxaparin) Page 2 of 113 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. TABLE OF CONTENTS ..............................................................................................................
    [Show full text]
  • Surfen, a Small Molecule Antagonist of Heparan Sulfate
    Surfen, a small molecule antagonist of heparan sulfate Manuela Schuksz*†, Mark M. Fuster‡, Jillian R. Brown§, Brett E. Crawford§, David P. Ditto¶, Roger Lawrence*, Charles A. Glass§, Lianchun Wang*, Yitzhak Torʈ, and Jeffrey D. Esko*,** *Department of Cellular and Molecular Medicine, Glycobiology Research and Training Center, †Biomedical Sciences Graduate Program, ‡Department of Medicine, Division of Pulmonary and Critical Care Medicine and Veteran’s Administration San Diego Medical Center, ¶Moores Cancer Center, and ʈDepartment of Chemistry and Biochemistry, University of California at San Diego, La Jolla, CA 92093; and §Zacharon Pharmaceuticals, Inc, 505 Coast Blvd, South, La Jolla, CA 92037 Communicated by Carolyn R. Bertozzi, University of California, Berkeley, CA, June 18, 2008 (received for review May 26, 2007) In a search for small molecule antagonists of heparan sulfate, Surfen (bis-2-methyl-4-amino-quinolyl-6-carbamide) was first we examined the activity of bis-2-methyl-4-amino-quinolyl-6- described in 1938 as an excipient for the production of depot carbamide, also known as surfen. Fluorescence-based titrations insulin (16). Subsequent studies have shown that surfen can indicated that surfen bound to glycosaminoglycans, and the extent block C5a receptor binding (17) and lethal factor (LF) produced of binding increased according to charge density in the order by anthrax (18). It was also reported to have modest heparin- heparin > dermatan sulfate > heparan sulfate > chondroitin neutralizing effects in an oral feeding experiments in rats (19), sulfate. All charged groups in heparin (N-sulfates, O-sulfates, and but to our knowledge, no further studies involving heparin have carboxyl groups) contributed to binding, consistent with the idea been conducted, and its effects on HS are completely unknown.
    [Show full text]
  • A 74-Year-Old Woman with Abdominal Pain and Fever
    A SELF-TEST IM BOARD REVIEW DAVID L. LONGWORTH, MO, JAMES K. STOLLER, MD, EDITORS OF CLINICAL PETER MAZZONE, MD CRAIG NIELSEN, MD RECOGNITION Department of Pulmonary and Critical Department of General Internal Care Medicine, Cleveland Clinic Medicine, Cleveland Clinic A 74-year-old woman with abdominal pain and fever 74-YEAR-OLD WOMAN was transferred pulmonary embolism, and a subsequent pul- from a local hospital for further evalua- monary angiogram was read as normal. A tion and management of abdominal pain with chest CT scan did not reveal anything other fever. than the small bilateral pleural effusions seen The patient had presented to the local on the chest radiograph. A thoracentesis hospital 11 days before with a 1-day history of revealed transudative fluid only. Intravenous bilateral upper-quadrant abdominal pain. She heparin was discontinued. described the pain as a constant ache with Past history. The patient had had essen- intermittent sharper pains accompanied by tial thrombocythemia for 5 years, for which nausea, but she could not identify any precip- she took hydroxyurea until 2 months before itants of the pain. She was also constipated. admission. Hydroxyurea was restarted at the A few days after being admitted to the local hospital because her platelet count was local hospital, the patient had developed a high at 750 x 109/L (normal 150-400 x fever and mild shortness of breath. She was 109/L), but it was stopped 3 days later because treated empirically for a possible pulmonary of mucositis. More than 30 years ago, the infection with a variety of antibiotics (ceftri- patient had been diagnosed with "pernicious Her platelet axone, ticarcillin-clavulanate, erythromycin, anemia.
    [Show full text]
  • Treatment of 51 Pregnancies with Danaparoid Because of Heparin
    ©2005 Schattauer GmbH,Stuttgart Blood Coagulation, Fibrinolysis and CellularHaemostasis Treatment of 51 pregnancies withdanaparoidbecause of heparin intolerance EdelgardLindhoff-Last1 ,Hans-Joachim Kreutzenbeck2 ,Harry N. Magnani3 1 Division ofVascular Medicine,Department of Internal Medicine,University Hospital Frankfurt, Germany 2 MedicalDepartment, Celltech, Essen, Germany 3 Clinical Consultant Marketing, OrganonBV, Oss,The Netherlands Summary Pregnant patients withacute venous thrombosis or ahistoryof required (3/14) or an adverse eventled to atreatment discon- thrombosis mayneed alternative anticoagulation, when heparin tinuation (11/14).Four maternal bleeding events were recorded intolerance occurs. Onlylimited dataonthe useofthe hepari- during pregnancy, deliveryorpostpartum, twoofthemwere noiddanaparoid areavailable in literature.We reviewedthe use fatal duetoplacental problems.Three fetal deathswererec- of danaparoid in 51 pregnancies of 49 patients identified in litera- orded,all associated with maternal complications antedating da- turebetween 1981 and 2004.All patients had developed hepa- naparoiduse.Danaparoid cross-reactivity was suspectedin4 rin intolerance (32 duetoheparin-induced thrombocytopenia, HITpatientsand 5non-HITpatientswith skin reactions and was 19 mainlydue to heparin-induced skin rashes)and had acurrent confirmedserologicallyinone of the twoHIT patients tested.In and/or pasthistoryofthromboembolic complications.The initial none of fivefetal cordblood- andthree maternal breast milk- danaparoid doseregimens ranged
    [Show full text]
  • The Evolving Role of Direct Thrombin Inhibitors in Acute Coronary
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE Journal of the American College of Cardiology providedVol. by 41, Elsevier No. 4 - SupplPublisher S Connector © 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. PII S0735-1097(02)02687-6 The Evolving Role of Direct Thrombin Inhibitors in Acute Coronary Syndromes John Eikelboom, MBBS, MSC, FRACP, FRCPA,* Harvey White, MB, CHB, DSC, FRACP, FACC,† Salim Yusuf, MBBS, DPHIL, FRCP (UK), FRCPC, FACC‡ Perth, Australia; Auckland, New Zealand; and Hamilton, Ontario, Canada The central role of thrombin in the initiation and propagation of intravascular thrombus provides a strong rationale for direct thrombin inhibitors in acute coronary syndromes (ACS). Direct thrombin inhibitors are theoretically likely to be more effective than indirect thrombin inhibitors, such as unfractionated heparin or low-molecular-weight heparin, because the heparins block only circulating thrombin, whereas direct thrombin inhibitors block both circulating and clot-bound thrombin. Several initial phase 3 trials did not demonstrate a convincing benefit of direct thrombin inhibitors over unfractionated heparin. However, the Direct Thrombin Inhibitor Trialists’ Collaboration meta-analysis confirms the superiority of direct thrombin inhibitors, particularly hirudin and bivalirudin, over unfractionated heparin for the prevention of death or myocardial infarction (MI) during treatment in patients with ACS, primarily due to a reduction in MI (odds ratio, 0.80; 95% confidence interval, 0.70 to 0.91) with little impact on death. The absolute risk reduction in the composite of death or MI at the end of treatment (0.8%) was similar at 30 days (0.7%), indicating no loss of benefit after cessation of therapy.
    [Show full text]
  • Avoiding Intelligence Failures in the Cardiac Catheterization Laboratory
    Review Avoiding Intelligence Failures in the Cardiac Catheterization Laboratory: Strategies for the Safe and Rational Use of Dalteparin or Enoxaparin during Percutaneous Coronary Intervention Jonathan D. Marmur, MD, Renee P. Bullock-Palmer, MD, Shyam Poludasu, MD, Erdal Cavusoglu, MD ABSTRACT: Low-molecular-weight heparin (LMWH) has been a of unstable angina (UA) and non-ST-segment elevation myocardial mainstay for the management of acute coronary syndromes (ACS) for infarction (NSTEMI). The ESSENCE and TIMI 11B trials support almost a decade. However, several recent developments have seriously the use of LMWH over unfractionated heparin (UFH) in acute coro - threatened the prominence of this drug class: (i) the adoption of an nary syndromes managed with a predominantly medical approach early invasive strategy, frequently leading to percutaneous coronary in - 1,2 tervention (PCI) where the dosing and monitoring of LMWH is un - as opposed to an invasive initial strategy. familiar to most operators, (ii) the results of the SYNERGY trial, which Since the publication of the ESSENCE and TIMI 11B trials, not only failed to establish the superiority of enoxaparin over unfrac - the management of acute coronary syndromes (ACS) has tionated heparin with respect to efficacy, but also demonstrated more evolved to favor an early invasive strategy. This evolution is sup - bleeding with LMWH, and (iii) the results of the REPLACE-2 and ported by a number of studies, including the FRISC II and the ACUITY trials, which have demonstrated the advantages of an ACS TACTICS TIMI-18 trials. 3,4 The Superior Yield of the New and PCI treatment strategy based on direct thrombin inhibition with bivalirudin.
    [Show full text]
  • Heparin-Induced Thrombocytopenia (Hit)
    HEPARIN‐INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the diagnosis and initial management of heparin‐induced thrombocytopenia (HIT) and suspected HIT. BACKGROUND: HIT is a transient, immune‐mediated adverse drug reaction in patients recently exposed to heparin that generally produces thrombocytopenia and often results in venous and/or arterial thrombosis. HIT occurs in up to 5% of patients receiving unfractionated heparin (UFH) and in <1% who receive low molecular weight heparin (LMWH). HIT is characterised by immunoglobulin G (IgG) antibodies that recognize an antigen complex of platelet factor 4 (PF4) bound to heparin. These antibodies trigger a highly prothrombotic state by causing intravascular platelet aggregation, intense platelet, monocyte and endothelial cell activation and excessive thrombin generation. CLINICAL FEATURES: HIT typically presents with a fall in platelet count with or without venous and/or arterial thrombosis. Thrombocytopenia: A platelet count fall >30% beginning 5‐10 days after heparin exposure, in the absence of other causes of thrombocytopenia, should be considered to be HIT, unless proven otherwise. A more rapid onset of platelet count fall (often within 24 hours of heparin exposure) can occur when there is a history of heparin exposure within the preceding 3 months. Bleeding is very infrequent. Thrombosis: HIT is associated with a high risk (30‐50%) of new venous or arterial thromboembolism. Thrombosis may be the presenting clinical manifestation of HIT or can occur during or shortly after the thrombocytopenia. Other clinical manifestations of HIT: Less frequent manifestations include heparin‐induced skin lesions, adrenal hemorrhagic infarction, transient global amnesia, and acute systemic reactions (e.g. chills, dyspnea, cardiac or respiratory arrest following IV heparin bolus).
    [Show full text]
  • Low Molecular Weight Heparins and Heparinoids
    NEW DRUGS, OLD DRUGS NEW DRUGS, OLD DRUGS Low molecular weight heparins and heparinoids John W Eikelboom and Graeme J Hankey UNFRACTIONATED HEPARIN has been used in clinical ABSTRACT practice for more than 50 years and is established as an effective parenteral anticoagulant for the prevention and ■ Several low molecular weight (LMW) heparin treatment of various thrombotic disorders. However, low preparations, including dalteparin, enoxaparin and molecularThe Medical weight Journal (LMW) of heparinsAustralia haveISSN: recently 0025-729X emerged 7 October as nadroparin, as well as the heparinoid danaparoid sodium, more2002 convenient, 177 6 379-383 safe and effective alternatives to unfrac- are approved for use in Australia. 1 tionated©The heparin Medical (BoxJournal 1). of AustraliaIn Australia, 2002 wwwLMW.mja.com.au heparins are ■ LMW heparins are replacing unfractionated heparin for replacingNew Drugs,unfractionated Old Drugs heparin for preventing and treating the prevention and treatment of venous thromboembolism venous thromboembolism and for the initial treatment of and the treatment of non-ST-segment-elevation acute unstable acute coronary syndromes. The LMW heparinoid coronary syndromes. danaparoid sodium is widely used to treat immune heparin- ■ induced thrombocytopenia. The advantages of LMW heparins over unfractionated heparin include a longer half-life (allowing once-daily or twice-daily subcutaneous dosing), high bioavailability and Limitations of unfractionated heparin predictable anticoagulant response (avoiding the need
    [Show full text]
  • Rtpa) for the Treatment of Hepatic Veno-Occlusive Disease (VOD
    Bone Marrow Transplantation, (1999) 23, 803–807 1999 Stockton Press All rights reserved 0268–3369/99 $12.00 http://www.stockton-press.co.uk/bmt Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD) S Kulkarni1, M Rodriguez2, A Lafuente2, P Mateos2, J Mehta1, S Singhal1, R Saso3, D Tait4, JG Treleaven3 and RL Powles1 Departments of 1Medical Oncology, 3Haematology and 4Radiotherapy, Royal Marsden NHS Trust, Sutton, Surrey, UK; and 2Haematology Department, Hospital La Paz, Madrid, Spain Summary: clinical syndrome characterized by hyperbilirubinemia, hepatomegaly and fluid retention,2,3 and results from dam- Seventeen patients who developed hepatic veno-occlus- age to structures in zone 3 of the liver acinus.4 In patients ive disease (VOD) following hematopoietic stem cell who have undergone hematopoietic stem cell transplan- transplantation were treated with recombinant tissue tation, chemoradiotherapy-induced endothelial cell damage plasminogen activator (rtPA) with or without heparin. is likely to be responsible for the pathogenesis of vessel rtPA was started a median of 13 days post transplant obstruction.5 (range 4–35). All patients received rtPA at a dose of 10 Treatment of established VOD has primarily been sup- mg/day as a starting dose, and 12 patients also received portive and any specific measures have resulted in little heparin (1500 U bolus; then 100 U/kg/day as a continu- impact on outcome. Based on the available evidence for ous i.v. infusion). The median number of days of rtPA involvement of hemostatic mechanisms and cytokines in therapy was 2.5 (1–12). The median total serum biliru- the pathogenesis of VOD,6–8 anti-thrombotic and anti-cyto- bin level was 116 mmol/l (range 63–194) at the begin- kine agents have been assessed for their role in treatment.
    [Show full text]
  • Transition of Anticoagulants 2019
    Transition of Anticoagulants 2019 Van Hellerslia, PharmD, BCPS, CACP, Brand Generic Clinical Assistant Professor of Pharmacy Practice, Angiomax bivalirudin Temple University School of Pharmacy, Philadelphia, PA Arixtra fondaparinux Bevyxxa betrixaban Pallav Mehta, MD, Assistant Professor of Medicine, Coumadin warfarin Division of Hematology/Oncology, Eliquis apixaban MD Anderson Cancer Center at Cooper, Camden, NJ Fragmin dalteparin Lovenox enoxaparin Reviewer: Kelly Rudd, PharmD, BCPS, CACP, Pradaxa dabigatran Clinical Specialist, Anticoagulation, Bassett Medical Center, Savaysa edoxaban Cooperstown, NY Xarelto rivaroxaban From To Action Apixaban Argatroban/ Wait 12 hours after last dose of apixaban to initiate parenteral anticoagulant. In cases of Bivalirudin/ high bleeding risk, consider omitting initial bolus when transitioning to heparin infusion. Enoxaparin/ Dalteparin/ Fondaparinux/ Heparin Apixaban Warfarin When going from apixaban to warfarin, consider the use of parenteral anticoagulation as a bridge (eg, start heparin infusion or therapeutic enoxaparin AND warfarin 12 hours after last dose of apixaban and discontinue parenteral anticoagulant when INR is therapeutic). Apixaban affects INR so that initial INR measurements during the transition may not be useful for determining the appropriate dose of warfarin. Apixaban Betrixaban, Wait 12 hours from last dose of apixaban to initiate betrixaban, dabigatran, edoxaban, or Dabigatran, rivaroxaban. Edoxaban, or Rivaroxaban Argatroban Apixaban, Start apixaban, betrixaban, dabigatran,
    [Show full text]
  • (Dipotassium Salt) and Heparin on the Estimation of Packed Cell Volume
    J Clin Pathol: first published as 10.1136/jcp.19.2.196 on 1 March 1966. Downloaded from J. clin. Path. (1966), 19, 196 Effect of ethylene-diamine-tetra-acetic acid (dipotassium salt) and heparin on the estimation of packed cell volume C. A. PENNOCK AND K. W. JONES From the Department of Haematology, Gibson Laboratories, Radcliffe Infirmary, Oxford SYNOPSIS The effect of varying concentrations of ethylene-diamine-tetra-acetic acid (E.D.T.A.) (dipotassium salt) and heparin on the estimation of packed cell volume has been studied using a microhaematocrit method. Varying concentrations of E.D.T.A. can produce serious errors in estimation of packed cell volume (P.C.V.) and reliable results are only obtained within the range of 1 to 2 mg./ml. Heparin is a more suitable anticoagulant for this investigation as varying the con- centration has little effect. Storage with either anticoagulant at suitable concentrations for 24 hours at room temperature has little influence on the results. The estimation ofthe packed cell volume (P.C.V.) is bottles are often returned to this laboratory contain- regarded as a reliable investigation in the diagnosis ing less than the recommended amount of blood.copyright. of anaemia, and errors in the estimation of mean Ethylene-diamine-tetra-acetic acid is known to corpuscular haemoglobin concentration (M.C.H.C.) cause distortion and shrinkage of red cells and are thought to be due more often to errors in the to affect the estimation of P.C.V. by conventional estimation of haemoglobin than of the P.C.V.
    [Show full text]
  • Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke a Randomized Controlled Trial
    Original Contributions Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke A Randomized Controlled Trial The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators Context.—Anticoagulation with unfractionated heparin is used commonly for ANTICOAGULATION with unfrac- treatment of acute ischemic stroke, but its use remains controversial because it has tionated heparin commonly is used to not been shown to be effective or safe. Low molecular weight heparins and hepa- treat persons with acute ischemic 1 rinoids have been shown to be effective in preventing deep vein thrombosis in per- stroke. However, the use of heparin re- mains controversial because it is not es- sons with stroke, and they might be effective in reducing unfavorable outcomes fol- 2-6 lowing ischemic stroke. tablished as safe or effective. A recent open trial demonstrated a modest effect Objective.—To test whether an intravenously administered low molecular from subcutaneously administered hep- weight heparinoid, ORG 10172 (danaparoid sodium), increases the likelihood of a arin in preventing recurrent stroke favorable outcome at 3 months after acute ischemic stroke. within 14 days but no improvement in Design.—Randomized, double-blind, placebo-controlled, multicenter trial. outcomes.7 Thus, whether an intrave- Setting and Participants.—Between December 22, 1990, and December 6, nously administered anticoagulant that 1997, 1281 persons with acute stroke were enrolled at 36 centers across the United would act more rapidly would be effec- States. tiveremainsunanswered.Thesearchfor Intervention.—A 7-day course of ORG 10172 or placebo was given initially as alternative medications that possess the a bolus within 24 hours of stroke, followed by continuous infusion in addition to the antithrombotic characteristics of hepa- best medical care.
    [Show full text]